医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

iPug, the Innovative Digital Health Platform Founded in Australia, Announces Their US Launch at the BIO International Convention 2016

2016年06月06日 AM09:45
このエントリーをはてなブックマークに追加


 

SAN FRANCISCO

iPug is a mobile friendly platform that transforms the way that research is conducted and how public health campaigns are delivered. With iPug Research Suite™, iPug recruits and engages targeted participants for high quality and real-time research results. iPug Health Suite also delivers individualized health campaigns to individuals with the right message, at the right time, on the right device with the right reward incentive, thereby moving governments away from a broadcast model of ineffective public service campaigns to a targeted reward-based communications platform. This level of engagement has proven to save time, money and has a higher success rate in influencing changed user behavior as it relates to public health.

Speaking on the emergence of digital health technology in the US and the opportunity for iPug, Steve Huff, CEO and Co-Founder of iPug, said, “It is an exciting time to be in digital health. Digital health funding is up with over $900m in investment in Q1 of this year. This represents a 50% year on year growth from the same time last year.”

After successfully launching in Australia and most notably developing the injury prevention app Cool Runnings for the Center for Children’s Burns and Trauma Research in Brisbane, iPug sees tremendous opportunity in the US to reduce public agency costs, effectively scale and deliver measurable results for public health campaigns.

At BIO, iPug will be at the Australian Pavilion from June 6-9th.

About iPug:

iPug is the world’s first mobile friendly platform that transforms the way that public research is conducted and how public health campaigns are delivered through mobile gamification.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160605005105/en/

CONTACT

iPug
Priya Ghandikota, 1 408-887-7094
press@ipug.co

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China
  • AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China
  • STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement
  • 新研究调查诊断性多通道睡眠检查之前采用Masimo SET®脉搏氧饱和度仪居家监测筛查唐氏综合征患儿罹患阻塞性睡眠呼吸暂停的风险
  • ダウン症候群の小児を対象とする睡眠時障害診断のマルチチャンネル研究に先立つ閉塞性睡眠時無呼吸症リスクのスクリーニングとしてMasimo SET®パルスオキシメトリーを使用するホームモニタリングの有用性を検討する新研究